SCHEMBL12451190

CC(=O)NC1[C@H](OC2[C@@H](O[C@@H]3C(O)[C@H](C)OC(CO[C@H]4OC(CO)[C@@H](O)[C@H](O)C4O[C@@H]4OC(CO)[C@@H](O[C@@H]5OC(CO[C@]6(C(=O)O)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O6)[C@H](O)[C@H](O)C5O)[C@H](O)C4NC(C)=O)[C@H]3O)OC(CO)[C@@H](O)[C@@H]2O)OC(CO)[C@@H](O[C@@H]2OC(CO[C@]3(C(=O)O)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O3)[C@H](O)[C@H](O)C2O)[C@@H]1O

nearest known ligand 0.57

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.57

▸	SELL	P14151	2/20	0.53

▸	SELP	P16109	1/20	0.53

▸	MAG	P20916	7/20	0.52

▸	SELE	P16581	4/20	0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17827374	1.00	SIGLEC7 (0.57)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16311983	0.96	SIGLEC7 (0.59)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16311992	0.96	SIGLEC7 (0.57)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16311993	0.95	SIGLEC7 (0.57)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16312001	0.95	SIGLEC7 (0.59)	SIGLEC7SELLSELPMAGSELE
SCHEMBL14416225	0.95	SIGLEC7 (0.62)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16312002	0.95	SIGLEC7 (0.56)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16311984	0.95	SIGLEC7 (0.56)	SIGLEC7SELLSELPMAGSELE
SCHEMBL16311987	0.95	SIGLEC7 (0.56)	SIGLEC7SELLSELPMAGSELE
SCHEMBL18193383	0.94	SIGLEC7 (0.55)	SIGLEC7SELLSELPMAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8809496-B2	Production method of 11-sugar sialylglycopeptide	THE NOGUCHI INSTITUTE (JP)	2014-08-19	—	—	US	disclosed
US-20120238723-A1	PRODUCTION METHOD OF 11-SUGAR SIALYLGLYCOPEPTIDE	THE NOGUCHI INSTITUTE (JP)	2012-09-20	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120238723-A1	PRODUCTION METHOD OF 11-SUGAR SIALYLGLYCOPEPTIDE	NEU4, NEU3, ST6GAL1	SIGLEC7 9/4885SELL 315/4885SELP 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.